The role of mitogen-activated protein (MAP) kinase in breast cancer.
about
Phosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cellsReciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cellsThe hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cellsEndocrine disruption via estrogen receptors that participate in nongenomic signaling pathwaysAntisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice.The signaling mucins Msb2 and Hkr1 differentially regulate the filamentation mitogen-activated protein kinase pathway and contribute to a multimodal response.MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancerPAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signalingCandidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancersComputational prediction and analysis of breast cancer targets for 6-methyl-1, 3, 8-trichlorodibenzofuranRadiation-induced molecular changes in rat mammary tissue: possible implications for radiation-induced carcinogenesisInvolvement of protein kinase C-dependent mitogen-activated protein kinase p44/42 signaling pathway for cross-talk between estradiol and transforming growth factor-beta3 in increasing basic fibroblast growth factor in folliculostellate cellsProliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/B6/F10 cells - the involvement of rapidly activated kinases and caspases.ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypesMolecular alterations in key-regulator genes among patients with T4 breast carcinoma.Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processesDetection of expressional changes induced by intrauterine growth restriction in the developing rat mammary gland via exploratory pathways analysis.GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness.Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.Estrogen-like effects of cadmium in vivo do not appear to be mediated via the classical estrogen receptor transcriptional pathwayPleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase.The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor.KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.Identification and pathway analysis of microRNAs with no previous involvement in breast cancer.Artemisia absinthium (AA): a novel potential complementary and alternative medicine for breast cancer.Effects of cadmium on estrogen receptor mediated signaling and estrogen induced DNA synthesis in T47D human breast cancer cells.Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated expression of HBO1Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1Modulation of protein kinase signaling cascades by palytoxin.WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancerClinical proteomics: translating benchside promise into bedside reality.Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness.The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathwayComplex prolactin crosstalk in breast cancer: new therapeutic implicationsPalytoxin: exploiting a novel skin tumor promoter to explore signal transduction and carcinogenesis.
P2860
Q24301472-2EDC9EA7-5517-4DD1-AA22-D3E6ACE0A1AEQ24310324-8D8FAD4D-FCCB-4A35-8347-8CB5B3F462F0Q24323230-FCD2446F-FF64-4515-9585-CB399BA35A45Q24595836-2A0B795B-7B9F-4C4F-8990-38657C97EF6DQ24628902-9A05530B-74B4-4BC2-A98F-934D82C3D09AQ25257729-36BF0A01-67FD-4AAE-B529-6CCB48125F7BQ27939105-7B3BEBE3-FEFE-49F2-AE7F-897D79C08DC0Q28114800-CCECC481-8056-490C-8329-916219B5B6B5Q28253621-2D90F91D-43A2-4724-9B77-6FF6182FDF98Q28265762-A1FD1E6D-2A4D-4734-9869-D575D40456B5Q28544666-BFD8E2FC-8F7C-4396-B288-DBB35A6A544AQ28577758-48CF762C-E38D-47EB-B222-8F32522A936FQ28584224-64819D6C-5F3D-46D3-A9AD-F77F698DC970Q33504908-73C5E2A2-2978-4468-B7C6-EA0031F2D05FQ33528959-F59F1791-DEC8-491D-AA9C-3363AADF91F7Q33608593-61CB5E1E-DD18-4BA5-9B1E-266E1EC55AC5Q33671525-D3FF0105-0D11-4B49-9D2A-7BBDC9B5C71FQ33740398-86B6EC41-744A-4360-8C05-4917BA2339BBQ33793606-87BB7A23-0296-4412-BFEE-31F9BF66896FQ33955127-753E80CA-C253-4E31-BCD1-19CDB61D30BBQ34074438-76DEB4AA-89C8-4743-B13F-5513522F461FQ34119145-25AA08F6-8D47-406F-8FDD-962501851B3CQ34155238-34FDF092-2014-4386-BF12-02B12F16E526Q34182706-26C9610A-BBA6-44EB-A311-290234D0A48DQ34205192-BB72CEF4-9A7A-45F4-8F49-4318006736A8Q34206037-D9FF781B-6C0F-4412-B189-D59603409B64Q34252582-0F13912F-984A-47C4-B11A-E8FC64927CFBQ34310691-9C78A2FC-097E-48BE-A370-2D3EDFD2C568Q34341395-64F3C39C-47C2-491A-8784-5472394C3374Q34484372-EFC3A704-DDCB-4F4B-8ED7-C75B395DABE2Q34592684-DB4B00EC-23FF-44C7-8FAE-A483193D7CC6Q34769445-994DD8F3-6139-461E-AB4E-F24955CEA71BQ34770011-24B45449-3557-4958-947F-1713A9F846F8Q34810370-7AA8BC63-B607-4462-B5DF-C9A361E4F86FQ35070726-42C985A7-5B02-4466-A9AC-0555202BB5FAQ35081944-5FC25066-DF53-4B54-962C-E0831FADD104Q35167772-24810184-A8E7-4CD1-87AA-9D368D468817Q35230305-9FE603C5-BF39-4606-B15A-938B4B299F50Q35303180-9D178763-E07F-4ECD-B250-66C19D7B4F08Q35585553-7404C517-5E4E-46A8-B47A-2A306A76CBF1
P2860
The role of mitogen-activated protein (MAP) kinase in breast cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@ast
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@en
type
label
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@ast
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@en
prefLabel
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@ast
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@en
P2093
P1476
The role of mitogen-activated protein (MAP) kinase in breast cancer.
@en
P2093
Liana Adam
Meei-Huey Jeng
Rakesh Kumar
Richard J Santen
Robert McPherson
Robert Xinde Song
P304
P356
10.1016/S0960-0760(01)00189-3
P577
2002-02-01T00:00:00Z